PureTech Health plc (LON:PRTC – Get Free Report) insider John LaMattina purchased 59,100 shares of the stock in a transaction that occurred on Tuesday, September 23rd. The shares were purchased at an average cost of GBX 125 per share, with a total value of £73,875.
PureTech Health Stock Up 1.1%
PureTech Health stock opened at GBX 126.80 on Thursday. The company’s 50-day moving average price is GBX 128.95 and its two-hundred day moving average price is GBX 129.60. The stock has a market cap of £306.46 million, a price-to-earnings ratio of 745.88 and a beta of 1.02. The company has a current ratio of 3.68, a quick ratio of 2.51 and a debt-to-equity ratio of 45.82. PureTech Health plc has a 52 week low of GBX 100.40 and a 52 week high of GBX 178.
Get PureTech Health alerts:
PureTech Health Company Profile
(Get Free Report)
PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.
Recommended Stories
Five stocks we like better than PureTech Health
5 discounted opportunities for dividend growth investors
Cybersecurity Market Set to Double: This ETF Offers Exposure
What is the Euro STOXX 50 Index?
Downgraded But Not Done: 3 Stocks Ready for a Market Comeback
Stock Analyst Ratings and Canadian Analyst Ratings
Solana Beat BTC and ETH in Q3: These 3 Stocks Saw It Coming
